These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. Madan RA; Antonarakis ES; Drake CG; Fong L; Yu EY; McNeel DG; Lin DW; Chang NN; Sheikh NA; Gulley JL J Natl Cancer Inst; 2020 Jun; 112(6):562-573. PubMed ID: 32145020 [TBL] [Abstract][Full Text] [Related]
24. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Patel PH; Kockler DR Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343 [TBL] [Abstract][Full Text] [Related]
25. Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects. Sheikh N; Cham J; Zhang L; DeVries T; Letarte S; Pufnock J; Hamm D; Trager J; Fong L Cancer Res; 2016 Jul; 76(13):3711-8. PubMed ID: 27216195 [TBL] [Abstract][Full Text] [Related]
26. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy. Gomella LG; Gelpi-Hammerschmidt F; Kundavram C Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724 [TBL] [Abstract][Full Text] [Related]
27. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Dawson NA; Roesch EE Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782 [TBL] [Abstract][Full Text] [Related]
28. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643 [TBL] [Abstract][Full Text] [Related]
29. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches. Arlen PM Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469 [No Abstract] [Full Text] [Related]
31. Sipuleucel-T: When and for Whom to Recommend It. Slovin SF Oncology (Williston Park); 2017 Dec; 31(12):900-1, 910-2. PubMed ID: 29297175 [TBL] [Abstract][Full Text] [Related]
33. The evolving role of immunotherapy in prostate cancer. Gerritsen WR Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924 [TBL] [Abstract][Full Text] [Related]
35. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Thara E; Dorff TB; Pinski JK; Quinn DI Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934 [TBL] [Abstract][Full Text] [Related]
36. How does sipuleucel-T alter our clinical practice? George D BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691 [No Abstract] [Full Text] [Related]
38. [Role of the Immune System and Possibilities of Immunotherapy in Prostate Cancer]. Kubáčková K Klin Onkol; 2015; 28 Suppl 4():4S69-72. PubMed ID: 26647892 [TBL] [Abstract][Full Text] [Related]
39. Cancer immunotherapy: sipuleucel-T and beyond. Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608 [TBL] [Abstract][Full Text] [Related]
40. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Mulders PF; De Santis M; Powles T; Fizazi K Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]